Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.60 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.54 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.51 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12398907 | 0.94 | GRM5 (0.62) | GRM5GABRA5CXCR2CXCR1L3MBTL1 | |
| SCHEMBL12398883 | 0.90 | GRM5 (0.59) | GRM5GABRA5CXCR2CXCR1L3MBTL1 | |
| SCHEMBL6930312 | 0.89 | GRM5 (0.58) | GRM5GABRA5CXCR2CXCR1 | |
| SCHEMBL6928889 | 0.86 | GRM5 (0.61) | GRM5GABRA5CXCR2CXCR1 | |
| SCHEMBL2158905 | 0.85 | GRM5 (0.60) | GRM5GABRA5 | |
| SCHEMBL6927979 | 0.83 | GABRA5 (0.67) | GRM5GABRA5 | |
| SCHEMBL6930872 | 0.83 | GRM5 (0.56) | GRM5GABRA5CXCR2CXCR1 | |
| SCHEMBL12398917 | 0.82 | GRM5 (0.57) | GRM5GABRA5CXCR2CXCR1 | |
| SCHEMBL12021026 | 0.81 | HPGDS (0.48) | GRM5GABRA5L3MBTL1HPGDS | |
| SCHEMBL6928789 | 0.79 | GRM5 (0.82) | GRM5GABRA5CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| WO-2011035324-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM1 | GRM5 1/4885GABRA5 26/4885CXCR2 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.